Takeda Pharmaceutical

Takeda establishes development center in China

Friday, February 10, 2012 09:54 AM

Takeda Pharmaceutical has established the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings (TCH), a wholly owned subsidiary of Takeda.

More... »

Takeda to cut 2,800 jobs as it absorbs Nycomed

Wednesday, January 18, 2012 12:21 PM

Osaka, Japan-based Takeda Pharmaceutical plans to consolidate its R&D site operations and cut its workforce by 2,800 to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture.

More... »

Takeda to integrate two subsidiaries in California

Wednesday, December 21, 2011 01:47 PM

Takeda Pharmaceutical will integrate two wholly-owned subsidiaries, Takeda San Diego (TSD) and Takeda San Francisco (TSF) on January 1, 2012. TSD will become the surviving company and change its name to Takeda California (TCAL) the same day. Keith Wilson, current president of TSD, will become the president of the new company.

More... »

Takeda to acquire Intellikine for $190 million

Wednesday, December 21, 2011 01:31 PM

Takeda Pharmaceutical and Intellikine have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.

More... »

Takeda acquires Nycomed for $13.7 billion

Tuesday, August 2, 2011 12:50 PM

Japanese drug maker Takeda Pharmaceutical secured EU approval for its $13.68 billion acquisition of privately owned Nycomed to reinforce its presence in emerging markets, according to Reuters.

More... »

Millenium expands on cancer treatment Velcade

Thursday, April 28, 2011 12:32 PM

Cambridge-based pharmaceutical company Millennium and their parent company Takeda Pharmaceutical, based in Japan, report they have submitted two supplemental new drug applications (NDAs) to the FDA for Velcade, a cancer treatment, according to Mass High Tech.

More... »

Takeda, Amgen phase III motesanib trial fails

Friday, April 1, 2011 10:53 AM

Amgen, Takeda Pharmaceutical, and Millennium, a division of Takeda, announced unfavorable results from the MONET1 pivotal phase III trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival.

More... »

Amylin & Takeda suspend obesity trial

Friday, March 18, 2011 10:24 AM

Amylin Pharmaceuticals and Takeda Pharmaceutical have suspended clinical activities in an ongoing phase II study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.

More... »

FDA approves Takeda's Edarbi

Tuesday, March 1, 2011 08:36 AM

Takeda Pharmaceutical’s blood pressure drug Edarbi has been approved by the FDA, according to PharmaTimes.

More... »